Philips showcases clinical data and solutions designed to deliver better cardiac care with greater efficiency at TCT 2022
September 16, 2022
- Global consensus data recommends the use of intravascular ultrasound (IVUS) in many peripheral vascular disease (PVD) procedures
- Philips Engagement Hub at TCT to feature a range of physician-led discussions, in-depth symposia, and hands-on trainings that address some of today’s most pressing cardiology challenges
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway and improve cardiac care experiences at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting (Boston, USA, September 16-19). In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.
“At Philips, we are fully focused on supporting physicians to improve the health and well-being of the patients they serve. Some of the most ground-breaking work we are doing to achieve this is happening in cardiology,” said Chris Landon, General Manager, Image Guided Therapy Devices at Philips. “TCT attendees will have the opportunity to see first-hand our complete set of solutions designed to provide clinicians with the diagnostic and therapeutic devices they need to optimize the workflow and improve outcomes for each individual patient.”
Lesen Sie auch
An interactive cardiology experience with Philips at TCT 2022
Visitors to TCT 2022 will have access to Philips’ latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions. Philips will be hosting hands on
demonstrations, symposia and discussions on topics that range from how to start an ultra-low contrast PCI program, to amplifying gender equality in medicine. Visitors will also have the opportunity
to learn more about Philips Azurion, the next generation image-guided therapy platform, Philips Interventional Applications Platform – IntraSight, which optimizes lab performance with its imaging, physiology and co-registration tools, and the
Philips iFR (Instant Wave-free Ratio) with its evidence-based methodology that improves outcomes, saves time, and reduces patient discomfort. Philips iFR
is the only resting index to earn a Class IA guideline recommendation from the ACC/AHA/SCAI and ESC based on clinical evidence of its accuracy [1, 2].